Cardiovascular Diabetology

ACE2 polymorphisms associated with cardiovascular risk in Uygurs with type 2 diabetes mellitus

Perivascular adipose tissue (PVAT) in atherosclerosis: a double-edged sword

Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats

MiR-21 protected against diabetic cardiomyopathy induced diastolic dysfunction by targeting gelsolin

The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study

Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus

Predictors of neutrophil extracellular traps markers in type 2 diabetes mellitus: associations with a prothrombotic state and hypofibrinolysis

Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study

Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction

HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients